PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE PLUS RITUXIMAB VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA – LOTIS‐5

Authors :: M. Chung
Carmelo Carlo-Stella
Mitul Gandhi
Yuliya Linhares
Mehdi Hamadani
D. Ungar
H. Adamis
Source :: Hematological Oncology. 39
Publication Year :: 2021
Publisher :: Wiley, 2021.

Subjects :: Cancer Research
medicine.medical_specialty
business.industry
Hematology
General Medicine
medicine.disease
Gastroenterology
law.invention
Oncology
Randomized controlled trial
law
Internal medicine
Relapsed refractory
medicine
Rituximab
In patient
business
Diffuse large B-cell lymphoma
medicine.drug

Tools